Women are leading the charge in the cannabis industry, and Helius is celebrating their success. The company has created a platform that provides women with the tools to succeed in this male-dominated industry.
Helius Celebrates Female Leadership In Cannabis Sector is a blog post by the company Helius. The company is celebrating female leadership in the cannabis sector and has released a list of stocks to watch. Read more in detail here: cbd stocks to watch.
Helius Therapeutics is commemorating Women’s Suffrage Day. New Zealand became the first country in the world to give women the right to vote on September 19, 1893.
After 128 years, New Zealand now has its third female Prime Minister, and almost half of its Parliamentarians are women. Women are also well-represented in the business sector, with a greater number of women in positions of leadership in research and healthcare.
Helius Therapeutics, the country’s biggest licensed medical cannabis business, is no exception. Helius is not just New Zealand’s first medical cannabis company to be granted a GMP Licence to Manufacture Medicines, but it is also headed by Carmen Doran, the company’s chief executive.
“Diversity of thought, perspectives, and experiences are valued at Helius. As a result, we’ve built a strong team with a healthy gender balance at all levels of the organization. Furthermore, Leila de Koster is the CEO of our subsidiary business, Hale Animal Health,” Ms Doran adds.
Helius has added Joanna Perry MNZM to its board of directors, as well as Mary Alice Simon as chief operational officer.
Helius is keen to guarantee that females, or wahine, are a major part of New Zealand’s newest health adventure, which sees local businesses set to produce medical cannabis products, based on research indicating that women make 80 percent of all healthcare choices for their families.
“Doctors are also important since medical cannabis is only accessible with a prescription. “That workforce, too, has changed dramatically in recent years, with new physicians now being mostly female,” she adds.
Ms Doran believes that this is an exciting moment for New Zealand’s newest industry, with huge possibilities to grow, employ, and export.
“All of the stakeholders in the business are working together to build our industry, and certainly, we all want to see more women driving the growth of medical cannabis in New Zealand. Our industry has gotten off to a fantastic start in terms of female representation thus far,” she adds.
Helius is dedicated to the development of new medicines that are both safe and effective, and it has a highly skilled staff to do so. Patients in New Zealand have long desired access to high-quality, low-cost medical cannabis. Their patience will be rewarded in the coming months.
Helius announced a partnership with Auckland University of Technology only days before Suffrage Day (AUT). Helius will collaborate with AUT on research and development of innovative medical cannabis products.
“We are ecstatic to be able to support three AUT PhD students who will be working on the next generation of cannabis medicines. It wasn’t by purpose that all three are female. Rather, all three are very bright young women who are the ideal match and possess the R&D enthusiasm required to achieve for patients,” Ms Doran explains.
Helius’ CEO is often invited to speak at business and healthcare events, as well as at secondary schools for females. More recently, I spoke to a Columba College Year 12 AgriBusiness class in Dunedin on the medical cannabis business, which piqued the students’ interest in potential possibilities in the new industry.
“In STEM disciplines, we are certainly witnessing a gender shift, with more young women pursuing science, technology, engineering, and math. More female scientists are emerging, similar to physicians, but New Zealand must maintain this trend,” she adds.
Ms. Doran is no stranger to the world of science. She has 15 years of expertise in the worldwide pharmaceuticals and animal health sectors, as well as a Master’s Degree in Biomedical Engineering and a Bachelor’s Degree in Mechanical Engineering.
“Just as Helius is developing an R&D pipeline to bring novel and interesting medicines to market, New Zealand must develop talent pipelines, beginning in elementary schools. That’s how we’ll keep the dial turning,” she adds.
Helius launched a second unique venture last year: New Zealand’s first medical cannabis firm for animal health.
Leila de Koster, the company’s co-founder and managing director, was instrumental in establishing Hale Animal Health. At its East Auckland offices, this company works with Helius Therapeutics.
“Hale now offers premium supplement products made entirely of natural components. Following that, we’ll start providing cannabis-related goods, such as scientifically validated animal medications. “It is an interesting and fast-paced industry,” Ms de Koster adds.
Diversity and inclusion, according to Carmen Doran, include a wide range of perspectives and experiences.
“At Helius, we bring together individuals from all walks of life, from cannabis production and research to pharmaceutical systems and commerce. “We will provide the best creative solutions for Kiwi patients and beyond via diversity and inclusion,” she adds.
Helius Therapeutics is a founding sponsor of MedCan Summit 2022, which will be held at the Cordis hotel in Auckland on the 10th and 11th of February next year.